Nektar Therapeutics (NKTR)
83.99
+0.77
(+0.93%)
USD |
NASDAQ |
Apr 16, 16:00
83.96
-0.04
(-0.04%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Quarterly) : 29.68M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 569.00M |
| Soleno Therapeutics, Inc. | 9.558M |
| Eli Lilly & Co. | 3.802B |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Esperion Therapeutics, Inc. | 13.93M |